Arrayit Corporation (ARYC)

[StockDetective]

Some folks fail to understand the importance of the immunotherapy partnerships that are forming. Allerdent has developed an immunotherapy treatment option that can be incorporated into something people do everyday (brushing your teeth). The success rate of patients accomplishing this particular program is far greater than all other options available if you look at the stats & read the studies performed. Further, they received a presentation award at a JP Morgan event and seeking FDA approval for peanut treatment (expected to be accomplished mid year 2021).

After researching this information, and viewing the demand chart presented in the investors briefing video one can see an exponential growth in the $ARYC allergy fingerstick test... This chart doesn’t seem to include demand if FDA approval for the peanut treatment is accomplished.

$ARYC may very well become a billion dollar company by 2021-2022 IMO.

https://www.globenewswire.com/news-release/2017/12/19/1266153/0/en/New-Test-and-Treatment-Allergy-Program-Enables-All-Physicians-To-Provide-Convenient-And-Effective-Allergy-Care.html

“The dried blood samples are sent to a PAS laboratory partner to be assessed for 145 different respiratory and food allergy sensitivities using a proprietary macroarray based technology. The laboratory sends the diagnostic report back to the clinician to be reviewed with the patient. The physician can then prescribe a personalized and convenient allergy immunotherapy for respiratory allergies in the form of a specialized toothpaste – Allerdent®.”

https://storage.googleapis.com/wzukusers/user-27922100/documents/5be9c697a0feacHGfCzT/01)%20PAS%20-%20Sales%20-%20Sample%20Report%20-%20110118-2.pdf

https://m.facebook.com/Pediatricallergysolutions/videos/?ref=page_internal&mt_nav=0

There were several tweets mentioning $ARYC expansion to the European Union last year.

Allovate Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy Platform

https://www.globenewswire.com/news-release/2019/03/08/1750672/0/en/Allovate-Therapeutics-Announces-Grant-of-European-Patent-Covering-Oral-Mucosal-Immunotherapy-Platform.html